Prevention of glucose-induced hypotension by the somatostatin analogue octreotide (SMS 201-995) in chronic autonomic failure: haemodynamic and hormonal changes.
1. The haemodynamic and hormonal changes following glucose ingestion (1 g/kg) were determined before and after pretreatment with either placebo or the somatostatin analogue, octreotide (SMS 201-995, 50 micrograms subcutaneously), in seven patients with chronic autonomic failure. 2. In the placebo phase, after glucose, there was a marked and prolonged fall in blood pressure with no change in cardiac index and peripheral blood flow. Plasma insulin and neurotensin levels increased, whereas glucagon, vasoactive intestinal polypeptide, noradrenaline and adrenaline levels were unchanged. 3. Octreotide transiently raised blood pressure and prevented glucose-induced hypotension. There were no changes in cardiac index or peripheral blood flow. Plasma insulin and neurotensin levels did not rise. Plasma glucose levels increased more slowly but reached a similar level to the placebo phase. 4. We conclude that in autonomic failure patients, glucose-induced hypotension was not accompanied by changes in cardiac index or peripheral blood flow, indicating a lack of compensation to probable splanchnic vasodilatation. The hypotension was prevented by the peptide release inhibitor, octreotide, with no change in cardiac index or in peripheral blood flow, suggesting an effect on the splanchnic vasculature, probably through inhibiting release of vasodilatatory pancreatic and gut peptides.
Raimbach
S J
SJ
Department of Medicine, St Mary's Hospital Medical School, University Department of Clinical Neurology, London.
Cortelli
P
P
Kooner
J S
JS
Bannister
R
R
Bloom
S R
SR
Mathias
C J
CJ
D000328:Adult; D001342:Autonomic Nervous System Diseases / Q000503:physiopathology*; D001786:Blood Glucose / Q000378:metabolism; D001794:Blood Pressure / Q000187:drug effects; D005260:Female; D005934:Glucagon / Q000097:blood; D005947:Glucose / Q000009:adverse effects*; D006801:Humans; D007022:Hypotension / Q000139:chemically induced / Q000517:prevention & control*; D007024:Hypotension, Orthostatic / Q000503:physiopathology; D007328:Insulin / Q000097:blood; D008297:Male; D008875:Middle Aged; D009496:Neurotensin / Q000097:blood; D009638:Norepinephrine / Q000097:blood; D015282:Octreotide / Q000627:therapeutic use*; D011188:Potassium / Q000097:blood; D013997:Time Factors; D014660:Vasoactive Intestinal Peptide / Q000097:blood
D001786:Blood Glucose; D007328:Insulin; D014660:Vasoactive Intestinal Peptide; D009496:Neurotensin; D005934:Glucagon; D005947:Glucose; D015282:Octreotide; D011188:Potassium; D009638:Norepinephrine